FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912395106> ?p ?o ?g. }

• W2912395106 endingPage "95" @default.
• W2912395106 startingPage "95" @default.
• W2912395106 abstract "95 Background: The treatment option for ESCC patients (pts) progressing after chemotherapy is still uncertain. Anlotinib is a multi-target tyrosine kinase inhibitor involved in tumor angiogenesis and growth, such as vascular endothelia growth factor receptor (VEGFR) 2/3, etc. Methods: Eligible pts were advanced ESCC who had progressed after platinum or taxane containing chemotherapy. Between January 6, 2016 and May 22, 2018, a total of 165 pts from 13 centers in China were randomly assigned (in a 2:1 ratio) to anlotinib arm (n=110), and placebo arm (n=55). Pts were given anlotinib (12 mg/day) or placebo orally from day 1 to day 14 in a 21-day cycle until disease progression or had unacceptable toxic effects. The primary end point was progression-free survival (PFS). Results: Median PFS was 3.0 months with anlotinib and 1.4 months with placebo (HR 0.5, 95% CI, 0.3-0.7; P<0.0001). Complete response occured in 2 pts with anlotinib and 0 pt with placebo. The objective response rates were 7% in the anlotinib group and 4% in the placebo group (P=0.498), and the disease control rates (DCR) were 64% and 18%, respectively (P<0.0001). In anlotinib arm, median duration of response was 5.8 months (range, 3.1-19.7+). Grade 3/4 treatment-related adverse events (TRAE) were reported in 36.7% and 11.0% of the two group pts, and grade 5 TRAE were 2.8% and 0%, respectively. The most common grade 3/4 TRAE (>5%) in anlotinib arm were hypertension (15.6%) and loss of appetite (5.5%). Median overall survival were similar between the groups (6.1 months vs 7.2 months; HR 1.2, 95%CI 0.8-1.8, P=0.4261). The ratio of pts received post study treatments was 41.2% (40/97) in anlotinib arm and 72.7% (40/55) in placebo arm (P=0.0002), including chemotherapy (23.7% vs 54.6%), PD-1 inhibitors (4.1% vs 11.0%), and Apatinib, a VEGFR inhibitor, (10.3% vs 20.0%), etc. Conclusions: In pretreated advanced ESCC pts, anlotinib significantly improved PFS and DCR compared with placebo, with a manageable safety profile. Clinical trial information: NCT02649361." @default.
• W2912395106 created "2019-02-21" @default.
• W2912395106 creator A5006389158 @default.
• W2912395106 creator A5022938518 @default.
• W2912395106 creator A5028614369 @default.
• W2912395106 creator A5029848730 @default.
• W2912395106 creator A5037658093 @default.
• W2912395106 creator A5037870558 @default.
• W2912395106 creator A5039152336 @default.
• W2912395106 creator A5041722972 @default.
• W2912395106 creator A5049189489 @default.
• W2912395106 creator A5060002817 @default.
• W2912395106 creator A5074904959 @default.
• W2912395106 creator A5082110547 @default.
• W2912395106 creator A5082185821 @default.
• W2912395106 creator A5084939652 @default.
• W2912395106 creator A5087661837 @default.
• W2912395106 date "2019-02-01" @default.
• W2912395106 modified "2023-10-18" @default.
• W2912395106 title "Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial." @default.
• W2912395106 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.95" @default.
• W2912395106 hasPublicationYear "2019" @default.
• W2912395106 type Work @default.
• W2912395106 sameAs 2912395106 @default.
• W2912395106 citedByCount "11" @default.
• W2912395106 countsByYear W29123951062020 @default.
• W2912395106 countsByYear W29123951062021 @default.
• W2912395106 countsByYear W29123951062022 @default.
• W2912395106 countsByYear W29123951062023 @default.
• W2912395106 crossrefType "journal-article" @default.
• W2912395106 hasAuthorship W2912395106A5006389158 @default.
• W2912395106 hasAuthorship W2912395106A5022938518 @default.
• W2912395106 hasAuthorship W2912395106A5028614369 @default.
• W2912395106 hasAuthorship W2912395106A5029848730 @default.
• W2912395106 hasAuthorship W2912395106A5037658093 @default.
• W2912395106 hasAuthorship W2912395106A5037870558 @default.
• W2912395106 hasAuthorship W2912395106A5039152336 @default.
• W2912395106 hasAuthorship W2912395106A5041722972 @default.
• W2912395106 hasAuthorship W2912395106A5049189489 @default.
• W2912395106 hasAuthorship W2912395106A5060002817 @default.
• W2912395106 hasAuthorship W2912395106A5074904959 @default.
• W2912395106 hasAuthorship W2912395106A5082110547 @default.
• W2912395106 hasAuthorship W2912395106A5082185821 @default.
• W2912395106 hasAuthorship W2912395106A5084939652 @default.
• W2912395106 hasAuthorship W2912395106A5087661837 @default.
• W2912395106 hasConcept C121332964 @default.
• W2912395106 hasConcept C126322002 @default.
• W2912395106 hasConcept C142424586 @default.
• W2912395106 hasConcept C142724271 @default.
• W2912395106 hasConcept C143998085 @default.
• W2912395106 hasConcept C197934379 @default.
• W2912395106 hasConcept C203092338 @default.
• W2912395106 hasConcept C204787440 @default.
• W2912395106 hasConcept C27081682 @default.
• W2912395106 hasConcept C2776694085 @default.
• W2912395106 hasConcept C2778019345 @default.
• W2912395106 hasConcept C2778695046 @default.
• W2912395106 hasConcept C2780739268 @default.
• W2912395106 hasConcept C31760486 @default.
• W2912395106 hasConcept C535046627 @default.
• W2912395106 hasConcept C71924100 @default.
• W2912395106 hasConcept C87355193 @default.
• W2912395106 hasConcept C90924648 @default.
• W2912395106 hasConceptScore W2912395106C121332964 @default.
• W2912395106 hasConceptScore W2912395106C126322002 @default.
• W2912395106 hasConceptScore W2912395106C142424586 @default.
• W2912395106 hasConceptScore W2912395106C142724271 @default.
• W2912395106 hasConceptScore W2912395106C143998085 @default.
• W2912395106 hasConceptScore W2912395106C197934379 @default.
• W2912395106 hasConceptScore W2912395106C203092338 @default.
• W2912395106 hasConceptScore W2912395106C204787440 @default.
• W2912395106 hasConceptScore W2912395106C27081682 @default.
• W2912395106 hasConceptScore W2912395106C2776694085 @default.
• W2912395106 hasConceptScore W2912395106C2778019345 @default.
• W2912395106 hasConceptScore W2912395106C2778695046 @default.
• W2912395106 hasConceptScore W2912395106C2780739268 @default.
• W2912395106 hasConceptScore W2912395106C31760486 @default.
• W2912395106 hasConceptScore W2912395106C535046627 @default.
• W2912395106 hasConceptScore W2912395106C71924100 @default.
• W2912395106 hasConceptScore W2912395106C87355193 @default.
• W2912395106 hasConceptScore W2912395106C90924648 @default.
• W2912395106 hasIssue "4_suppl" @default.
• W2912395106 hasLocation W29123951061 @default.
• W2912395106 hasOpenAccess W2912395106 @default.
• W2912395106 hasPrimaryLocation W29123951061 @default.
• W2912395106 hasRelatedWork W2000255330 @default.
• W2912395106 hasRelatedWork W2050516500 @default.
• W2912395106 hasRelatedWork W2060982698 @default.
• W2912395106 hasRelatedWork W2064879719 @default.
• W2912395106 hasRelatedWork W2085830368 @default.
• W2912395106 hasRelatedWork W2144717536 @default.
• W2912395106 hasRelatedWork W2154108301 @default.
• W2912395106 hasRelatedWork W3009513461 @default.
• W2912395106 hasRelatedWork W4205833447 @default.
• W2912395106 hasRelatedWork W4382654797 @default.
• W2912395106 hasVolume "37" @default.
• W2912395106 isParatext "false" @default.
• W2912395106 isRetracted "false" @default.

• next